MDNAF Medicenna Therapeutics Corp. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1807983 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2023-03-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2023Q4*2023-03-31 | 2022Q4*2022-03-31 | 2021Q4*2021-03-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| Net income | -10.05M | -22.58M | -17.29M |
| EPS (diluted) | — | — | — |
| Balance sheet | |||
| Cash & equivalents | 33.60M | 20.54M | 30.38M |
| Current assets | 36.38M | 23.39M | 42.15M |
| Intangibles | 61,000 | 65,000 | 71,000 |
| Total assets | 36.45M | 23.46M | 42.25M |
| Current liabilities | 3.80M | 2.62M | 4.11M |
| Total liabilities | 6.96M | 2.62M | 4.11M |
| Shareholders' equity | 29.49M | 20.84M | 38.15M |
| Shares outstanding | 69.64M | 55.65M | 53.55M |
| Cash flow statement | |||
| Operating cash flow | -12.66M | -23.58M | -15.31M |
| Investing cash flow | 0 | 10.05M | 5.01M |
| Financing cash flow | 24.76M | 3.88M | 18.26M |
| Stock-based compensation | 1.37M | 1.42M | 1.01M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.